pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·18h ago·2 min read
save

Sellas marks 9-month survival benefit in late-stage leukemia vaccine study

Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.

Nov 16, 2026·read at Fierce Biotech ↗

Biotech Sellas marks 9-month survival benefit in late-stage leukemia vaccine study By Michael Gibney Nov 17, 2026 7:00am SELLAS Life Sciences acute myeloid leukemia Biotech Clinical Data Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia (AML) has passed a phase 3 test with a more than nine-month improvement in overall survival. The peptide vaccine, called galinpepimut-S (GPS), is Sellas’ lead candidate and targets the WT1 protein present in several tumor types. The phase 3 AML trial met its primary endpoint, with GPS delivering a median overall survival of 24 months versus less than 15 months for best available therapy.

GPS also showed a 41% reduction in the risk of death. The patients in the trial had been in remission with AML either completely or at least twice but still lacked platelet recovery and had undergone multiple salvage therapies or were ineligible for stem cell treatment. Among 126 patients split between GPS alone and treatments including chemotherapy and AbbVie and Roche’s Venclexta, Sellas last year found it took longer than anticipated to reach the number of patient deaths required for the final analysis.

The company had been awaiting 80 patient deaths, which had not occurred until late October this year. Safety and tolerability were normal, and Sellas plans to begin an accelerated filing with the FDA. The drug, which was licensed from Memorial Sloan Kettering Cancer Center, was granted an orphan designation from the agency in 2023.

“The magnitude of the survival benefit observed with our investigational GPS cancer vaccine immunotherapy represents a defining milestone for Sellas and provides phase 3 validation of our WT1-targeted immunotherapeutic technology,” Sellas CEO Angelos Stergiou, M.D., said in a release. “We believe GPS has the potential to become an important paradigm-shifting option for this high-risk population that desperately needs effective therapies.” GPS is lined up in a number of clinical programs, including a mid-stage monotherapy trial for malignant pleural mesothelioma, as well as combinations with Bristol Myers Squibb’s Opdivo and Merck’s Keytruda. Sellas also has a small molecule called SLS009 for AML and will present response and survival outcomes next month at the annual meeting of the American Society of Hematology.

SELLAS Life Sciences acute myeloid leukemia Biotech Clinical Data

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
366 words · retrieved just now
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 10h agoLilly signs $5.9B deal with Stipple to unlock oncology targetsFierce Biotech
  • 1d agoCG preps new, expanded bladder cancer plans with FDA after ph. 3 winFierce Biotech
  • 1d agoBiogen inks $411M neurodegeneration pact with protein degrader biotech TrimTechFierce Biotech
  • 1d agoHelus' chemically modified psychedelic hits key goals in phase 3 depression trialFierce Biotech
  • 1d agoJ&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificFierce Biotech